Endosys Technologies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 06-12-2024
- Paid Up Capital ₹ 0.10 M
as on 06-12-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 299.62%
(FY 2022)
- Profit 1093.99%
(FY 2022)
- Ebitda 1087.46%
(FY 2022)
- Net Worth 124.62%
(FY 2022)
- Total Assets 47.63%
(FY 2022)
About Endosys Technologies
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Prasad, Khaza Jayasree, and Venkata Santharam serve as directors at the Company.
- CIN/LLPIN
U52190TN2016PTC111115
- Company No.
111115
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Endosys Technologies Private Limited offer?
Endosys Technologies Private Limited offers a wide range of products and services, including Cleaning Liquids & Wipes, Cleaning Chemicals, Bathroom Accessories, Soap & Sanitizer Dispenser, Autoclaves, Sterilizers & Incubators, Laboratory Autoclave & Sterilizers, Surgical Trays, Sterilization Tray, Dietary Supplements, L-Lysine.
Who are the key members and board of directors at Endosys Technologies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Prasad  | Director | 24-Jun-2016 | Current |
| Khaza Jayasree | Director | 24-Jun-2016 | Current |
| Venkata Santharam | Director | 24-Jun-2016 | Current |
Financial Performance of Endosys Technologies.
Endosys Technologies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 299.62% increase. The company also saw a substantial improvement in profitability, with a 1093.99% increase in profit. The company's net worth Soared by an impressive increase of 124.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Endosys Technologies?
In 2022, Endosys Technologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Endosys Technologies?
Unlock and access historical data on people associated with Endosys Technologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Endosys Technologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Endosys Technologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
